

patients) were also found with other techniques (2 with ultrasound used in the standard clinical workup in symptomatic patient). Tomosynthesis is promising for lesion detection and lesion characterisation because of reduced superposition. In symptomatic patients the role of tomosynthesis is not yet fully established, but this technique might be useful, especially when used in combination with mammography.

176

Poster Discussion

Examination of sentinel lymph node in breast cancer by the combination of computed tomography lymphography, blue dye method and fluorescence navigation

K. Komuro¹, Y. Nakanishi¹, N. Iwashiro¹, M. Ohara¹, M. Ishizaka¹, S. Takeda², R. Kaneko², Y. Ogasawara², K. Yonezawa³. ¹Hakodate National Hospital, Surgery, Hakodate, Japan; ²Hakodate National Hospital, Radiology, Hakodate, Japan; ³Hakodate National Hospital, Clinical Research, Hakodate, Japan

Background: The sentinel lymph node (SLN) biopsy technique is established in the treatment of breast cancer. It is considered that the combination of scintigraphic and blue dye method is needed for SLN biopsy. Recently, computed tomography lymphography (CTLG) with iopamidol and fluorescence navigation with indocyanine green (ICG) was developed for detecting SLN in breast cancer.

We examined efficacy of CTLG and fluorescence navigation.

Method: An iopamidol was injected subareolarly in 51 patients with operable breast cancer. Within two minutes after the 15–30 sec gentle massage of the injection sites, 1.25 mm-thick cross-sectional CT images of the breast and axilla were taken. These images were reconstructed into 3D images to identify the location, size and number of the SLN. All the subjects underwent blue dye method SLNB.

SLNB using the fluorescence navigation was performed in the last 15 patients.

Fluorescence images were obtained using an ICG fluorescence high sensitivity near-infrared video camera system (PDE: Hamamatsu Photonics, Hamamatsu, Japan). When ICG was injected subareolarly, subcutaneous lymphatic vessels draining from the areola to the axilla were visible by fluorescence within a few minutes. The SLN was then dissected by CTLG and fluorescence navigation.

A backup axillary dissection was performed on 31 patients. The accuracy of the procedure was evaluated histologically.

Results: A backup axillary dissection was performed on 31 patients, the identification rate was 93.5% and the false-negative rate was 12.5% (1/8 patients). The identification rate in CTLG was 100% afterwards. Subcutaneous lymphatics and SLN were detectable by fluorescence in all patients. The presumptive region of the skin incision was the same as CTLG by the fluorescence navigation for all cases. There was the case that SLN was not stained with by blue dye method.

Conclusion: SLN navigation by ICG fluorescence imaging and CTLG are a promising technique for further clinical exploration.

177

Poster Discussion

Significance of preoperative Fluorodeoxyglucose-PET for detection of axillary lymph node metastasis

H. Kim¹, J. Lee¹, J. Kim¹, E. Chang¹. ¹Chungnam National University Hospital, Surgery, Daejeon, South Korea

Introduction: The axillary lymph node status is still considered the single most important prognostic indicator in patients who have breast cancer. Clinical examination is generally unreliable for staging the axilla. Lack of conventional imaging techniques to determine the axillary lymph node involvement with acceptable accuracy has been the main reason for axillary lymph node dissection; however, up to 70% of patients who have stage T1 and T2 tumors have negative axillary lymph nodes. The extent, morbidity, and cost of the staging procedure of axillary lymph node dissection are often greater than those of the surgical treatment of the primary tumor. In anatomical based imaging modalities, such as computed tomography, ultrasound, and MRI, the size of a particular lymph node is of crucial importance to determine the tumor involvement. Generally, lymph node enlargement over 1 cm in diameter is the decisive criterion. In contrast, metabolic imaging with FDG-PET is suggested to provide more specific information, based on detecting increased glucose consumption of cancer tissue. This study was undertaken to evaluate the diagnostic accuracy of preoperative positron emission tomography.

Methods: A retrospective review from January of 2007 to December of 2007 was performed in all patients (n = 109) undergoing a preoperative FDG-PET. PET imaging with the radiolabeled glucose analogue (F-18 FDG) was used to visualize the primary breast tumor and metastatic lesions.

Results: In 109 patients, the sensitivity and specificity of PET for detection of axillary lymph node metastasis were 74% and 80%,

respectively. Overall accuracy was 79%. In patients (n = 42) who had primary breast tumors larger than 2 cm (>stage pT1), the sensitivity increased of 100%, with corresponding specificity of 82.3%.

Conclusion: FDG-PET cannot replace the axillary dissection, not only because of the limited sensitivity, but also because the number of involved lymph nodes and extranodal extension cannot be determined. But, among patients who have larger tumors, sentinel biopsy can be avoided in those who have positive FDG-PET, in whom complete axillary lymph node dissection should be the primary procedure.

Wednesday, 16 April 2008

12:30–14:30

POSTER SESSION

Tumour biology and immunology

178

Poster

Breast cancer-derived factors stimulate ERK-mediated survival of osteoclasts and limit the effectiveness of bisphosphonates in treatment of bone metastases

O. Hussein¹, K. Teidemann¹, S.V. Komarova¹. ¹McGill University, Faculty of Dentistry, Montreal, Canada

Introduction: Bone metastasis is a common complication of advanced breast cancer, which causes distressing symptoms, including pathological fractures and bone pain. Osteoclasts are critical mediators of bone osteolysis induced by breast cancer. Moreover, osteoclasts further drive tumor growth by releasing IGF and TGF- β stored in the bone matrix. Osteoclast-directed therapy is thus an ideal strategy to treat breast cancer metastases to bone. Bisphosphonates are the only available anti-osteoclastic agents used in metastases but their effect is limited in the metastatic setting relative to other osteolytic conditions. We sought the explanation of osteoclast resistance to bisphosphonates and the potential avenues to inhibit osteoclasts in breast cancer metastatic bones.

Materials and Methods: Osteoclasts formed from RAW 264.7 cells under effect of the physiological osteoclastogenic mediator RANKL (50ng/ml) were treated with Alendronate for 48 hours in the presence or absence of conditioned media from the MDA-MB-231 breast cancer cell line culture. The numbers of multinucleated osteoclasts stained positive for tartrate-resistant acid phosphatase were assessed in parallel samples, and the levels of ERK1/2 phosphorylation were determined by immunoblotting. Some cultures were treated with the ERK inhibitor PD98059.

Results: Raw 264 cells develop mature osteoclasts after 5 days of treatment with RANKL. Exposure of mature osteoclasts to 10% MDA-MB-231 conditioned media significantly increased the cell count at day 7 compared to cultures that were continuously treated with RANKL treatment, indicating that soluble mediators released from breast cancer cells support osteoclast survival in vitro. ERK pathway has been previously shown to play a critical role in osteoclast survival. We have found that exposure to soluble factors from breast cancer cells strongly induced phosphorylation of ERK1/2 in mature osteoclasts. Alendronate treatment of RANKL-treated mature osteoclasts resulted in significant and dose-dependent decrease in the osteoclasts count. In contrast, in the presence of breast cancer-derived factors, mature osteoclasts failed to respond to alendronate in the concentration range from 10^{-8} to 10^{-4} M, demonstrating that osteoclast exposed to breast cancer soluble factors are resistant to the apoptotic effect of alendronate. Inhibition of ERK pathway using PD98059 ($10 \mu\text{M}$) before treatment with Alendronate (10^{-4} M) partially restored the responsiveness of mature osteoclast to Alendronate.

Conclusion: Osteoclasts exposed to cancer-derived factor demonstrate improved survival likely counteracting pro-apoptotic effects of alendronate. Identification of the mechanism of alendronate resistance in breast metastases may pave the way to more effective breast cancer bone metastases.

179

Poster

CD44+/CD24-/low cells derived from long-term cultured human breast carcinosarcoma

W. Han¹, K.M. Lee², J.B. Kim², E. Ko¹. ¹Seoul National University College of Medicine, Dept of Surgery, Seoul, Korea; ²Seoul National University College of Medicine, Cancer Research Institute, Seoul, Korea

The CD44+/CD24-/low cells have been recently identified as breast cancer-initiating cells. They retain tumorigenicity in vivo and display stem cell-like properties. We have obtained CD44+/CD24-/low (>90%) cells from carcinosarcoma using mammosphere culture method which was previously